(Bloomberg) Novartis AG is taking a big step off the sidelines of the pandemic, seeking emergency approval for an experimental Covid-19 medicine. The move carries even greater import for the Swiss drugmaker’s partner, a small biotech that has struggled to get its medicines to market.